86.96 -0.08 (-0.09%)
After hours: 5:59PM EDT
|Bid||86.21 x 2200|
|Ask||88.10 x 900|
|Day's Range||86.02 - 87.08|
|52 Week Range||66.77 - 87.14|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
Small-cap stocks and the related small-cap ETFs, including the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, are equity market leaders this year. Keeping the the small-cap’s momentum going, traders believed smaller companies were insulated from the overseas turmoil. “Small-cap companies tend to source a larger portion of their revenue domestically compared to large caps,” according to BlackRock. “As such, they pay an estimated corporate tax rate of around 32% vs. 28% for larger firms.
For example, the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, surged last week, bringing its year-to-date gain to over 12%. Keeping the the small-cap’s momentum going, traders believed smaller companies were insulated from the overseas turmoil.
Small-Cap ETFs are leading the markets charge this year. Year-to-date, the iShares Core S&P Small-Cap ETF (NYSEArca: IJR), which tracks the S&P Small-Cap 600 Index, increased 10.9%; the iShares Russell ...
While the U.S. and China are embroiled in an escalating trade war, small-cap stocks and small-cap ETFs are outperforming. Year-to-date, the iShares Core S&P Small-Cap ETF (IJR) , which tracks the S&P Small-Cap 600 Index, increased 13.2% and the iShares Russell 2000 ETF (IWM) , which tracks the benchmark Russell 2000 Index, gained 11.8% year-to-date while the S&P 500 was up 4.5%. Supporting the small-cap's recent run up, many traders believed smaller companies were insulated from the overseas turmoil.
The S&P SmallCap 600 Index has outperformed the benchmark S&P 500 Index of large-cap companies by 9.5% from February through May, marking an outperformance at the three-month premium level last seen since May 2002, according to a S&P Dow Jones Indices note. The SPDR S&P 600 Small Cap ETF (SLY), iShares Core S&P Small-Cap ETF (IJR) and Vanguard S&P Small-Cap 600 ETF (VIOO) , which all track the S&P SmallCap 600 Index, have increased 10.4% over the past three months, whereas the S&P 500 gained 2.6%. Jodie Gunzberg, Managing Director, Head of U.S. Equities, S&P Dow Jones Indices, pointed to a number of supporting factors that have helped small-caps outperform and may continue to bolster this market category ahead.
Both the Russell 2000 and S&P 600 indices hit all-time highs last week as investors continued to jump on the small-cap bandwagon. Can anything stop small-cap stocks from moving higher over the remainder of 2018? A recession would halt them in their tracks, but barring the unthinkable, you might want to consider selling some of your large-cap holdings for small-cap stocks or exchange-traded funds because they’re hotter than a pistol.
There is no doubt about it: small-cap stocks and the related exchange traded funds are in rally mode. The iShares Russell 2000 ETF (NYSEArca: IWM), which tracks the benchmark Russell 2000 Index, is up ...
Energy stocks are finding new life as oil prices climb and climb. Shares have been dead money for a while and seemed totally disconnected from crude prices, but investors have since come around. In a scan of more than 2,100 ETFs that closed last week at new highs relative to the MSCI All-Country World Index, energy ETFs "dominate" both on an absolute and relative basis, as Ned Davis Research Group's ETF strategist Will Geisdorf wrote in a report published Monday.
The Federal Reserve typically hikes interest rates to obviate an overheating economy during the later stages of an economic cycle, typically foreshadowing the eventual end of a bull market. Nevertheless, ...
It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.
On June 19, 2017, Melinta Therapeutics announced that its drug, Baxdela, had secured regulatory approval from the FDA as a treatment option for adult patients suffering from acute bacterial skin and skin ...